Shares of Opthea Limited (NASDAQ:OPT - Get Free Report) gapped down before the market opened on Tuesday . The stock had previously closed at $5.21, but opened at $5.06. Opthea shares last traded at $5.21, with a volume of 24,990 shares.
Analysts Set New Price Targets
A number of research analysts recently weighed in on the company. Canaccord Genuity Group raised Opthea to a "strong-buy" rating in a research note on Tuesday, December 17th. HC Wainwright reiterated a "buy" rating and set a $12.00 price objective on shares of Opthea in a report on Wednesday, January 29th.
Get Our Latest Stock Analysis on OPT
Opthea Trading Up 0.6 %
The business's fifty day moving average price is $4.37 and its 200-day moving average price is $3.89.
Institutional Investors Weigh In On Opthea
A number of institutional investors and hedge funds have recently bought and sold shares of OPT. ABC Arbitrage SA purchased a new position in shares of Opthea in the 4th quarter worth approximately $40,000. OLD Mission Capital LLC purchased a new position in shares of Opthea in the 4th quarter worth approximately $42,000. Citadel Advisors LLC purchased a new position in shares of Opthea in the 4th quarter worth approximately $79,000. Twin Lakes Capital Management LLC purchased a new position in shares of Opthea in the 3rd quarter worth approximately $81,000. Finally, Jane Street Group LLC purchased a new position in shares of Opthea in the 3rd quarter worth approximately $114,000. 55.95% of the stock is owned by hedge funds and other institutional investors.
About Opthea
(
Get Free Report)
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
See Also
Before you consider Opthea, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Opthea wasn't on the list.
While Opthea currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
